Cargando…

REGEN‐COV antibody combination in patients with lymphoproliferative malignancies and SARS‐CoV‐2 infection

Patients with lymphoproliferative diseases are at high risk for SARS‐CoV‐2‐related complications and mortality. The role of casirivimab and imdevimab (REGEN‐COV), a neutralizing antibody cocktail, to treat immunocompromised hemato‐oncological patients with SARS‐CoV‐2 disease 2019 (Covid‐19) remains...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bronstein, Yotam, Avivi, Irit, Cohen, Yael C, Feigin, Eugene, Perry, Chava, Herishanu, Yair
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110987/ https://www.ncbi.nlm.nih.gov/pubmed/35602247 http://dx.doi.org/10.1002/jha2.403

Ejemplares similares

PB2288: INCIDENCE OF NEWLY DIAGNOSED AGGRESSIVE NON-HODGKIN’S LYMPHOMA BEFORE AND DURING THE COVID-19 PANDEMIC IN ISRAEL - A SINGLE CENTER RETROSPECTIVE STUDY
por: Bronstein, Yotam, et al.
Publicado: (2023)

COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge
por: Bronstein, Yotam, et al.
Publicado: (2022)

Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia
por: Herishanu, Yair, et al.
Publicado: (2022)

Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy
por: Cohen, Dan, et al.
Publicado: (2021)

Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells
por: Shorer Arbel, Yamit, et al.
Publicado: (2021)

The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients
por: Saiag, Esther, et al.
Publicado: (2022)

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
por: Herishanu, Yair, et al.
Publicado: (2021)

Lower Patient Anxiety and Unchanged Levels of Adherence to Hemato-Oncologic Treatment in Response to New Measures to Reduce Hospital Exposure Risk to COVID-19
por: Sarid, Nadav, et al.
Publicado: (2021)

Is There a Role for [(18)F]FDG PET-CT in Staging MALT Lymphoma?
por: Cohen, Dan, et al.
Publicado: (2022)

The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge
por: Bronstein, Yotam, et al.
Publicado: (2022)

COVID-19 in patients with CLL: how can we change the odds?
por: Herishanu, Yair, et al.
Publicado: (2021)

Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
por: Shapiro, Mika, et al.
Publicado: (2017)

The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma
por: Perry, Chava, et al.
Publicado: (2016)

Rituximab-Related Pulmonary Toxicity
por: Herishanu, Yair, et al.
Publicado: (2010)

Feasibly of CD24/CD11b as a Screening Test for Hematological Malignancies
por: Shapira, Shiran, et al.
Publicado: (2021)

Flow Cytometry-based Detection of B-cell Lymphoproliferative Disorders in Patients with Mycosis Fungoides
por: GELLER, Shamir, et al.
Publicado: (2020)

B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders
por: Tanguay, Mégane, et al.
Publicado: (2022)

Spatial organization and early signaling of the B-cell receptor in CLL
por: Shorer Arbel, Yamit, et al.
Publicado: (2022)

COVID-19 Breakthrough Infections in Vaccinated Patients With CLL in Israel
por: Yekutiel, Naama, et al.
Publicado: (2023)

Tear antibodies to SARS‐CoV‐2: implications for transmission
por: Selva, Kevin J, et al.
Publicado: (2021)

Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant
por: Qu, Panke, et al.
Publicado: (2022)

Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study
por: Ram, Ron, et al.
Publicado: (2021)

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
por: Weinreich, David M., et al.
Publicado: (2021)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
por: O’Brien, Meagan P., et al.
Publicado: (2021)

Assessment of commercial SARS-CoV-2 antibody assays, Jamaica
por: Butterfield, Tiffany R., et al.
Publicado: (2021)

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
por: O’Brien, Meagan P., et al.
Publicado: (2021)

Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention
por: O’Brien, Meagan P., et al.
Publicado: (2021)

Malignant Lymphoproliferative Diseases
por: Garrett, J. V.
Publicado: (1981)

Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies
por: Sekirov, Inna, et al.
Publicado: (2021)

Duration of anti-SARS-CoV-2 antibodies much shorter in India
por: Kumar, Nishant, et al.
Publicado: (2021)

Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New Zealand
por: Whitcombe, Alana L, et al.
Publicado: (2021)

Long‐term persistence of neutralizing SARS‐CoV‐2 antibodies in pets
por: Decaro, Nicola, et al.
Publicado: (2021)

Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization
por: Guo, Huimin, et al.
Publicado: (2022)

Prevalence of SARS-CoV-2 antibodies in the Republic of Congo in mid-2021
por: Niama, Fabien R., et al.
Publicado: (2022)

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
por: Copin, Richard, et al.
Publicado: (2021)

Factors Influencing Antibody Response to SARS-CoV-2 Vaccination
por: Kodde, Cathrin, et al.
Publicado: (2023)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
por: Abdelghany, T.M., et al.
Publicado: (2021)

Fatal SARS-CoV-2 coinfection in course of EBV-associated lymphoproliferative disease
por: Roncati, Luca, et al.
Publicado: (2020)

Subcutaneous REGEN-COV antibody administration in a community pharmacy
por: Dougherty, Tyler S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vub2nkjrja6fu592svn1vun5jj